BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/6/2018 1:12:00 PM | Browse: 378 | Download: 139
Publication Name World Journal of Gastroenterology
Manuscript ID 38855
Country/Territory Japan
2018-03-28 06:11
Peer-Review Started
2018-03-28 11:15
To Make the First Decision
2018-04-11 07:30
Return for Revision
2018-04-13 06:29
2018-04-15 02:53
Second Decision
2018-04-23 05:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-04-23 16:31
Articles in Press
2018-04-23 16:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-05-04 10:01
Publish the Manuscript Online
2018-05-06 13:12
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Naofumi Mukaida and Yasunari Nakamoto
Author(s) ORCID Number
Naofumi Mukaida http://orcid.org/0000-0002-4193-1851
Yasunari Nakamoto http://orcid.org/0000-0002-3160-3555
Funding Agency and Grant Number
Funding Agency Grant Number
Research Programs on the Innovative Development and Application for New Drugs for Hepatitis B 17fk0310116h0001
Corresponding author Naofumi Mukaida, MD, PhD, Professor, Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan. mukaida@staff.kanazawa-u.ac.jp
Keywords Natural killer T cell; Natural killer cell; Chimeric antigen receptor T cell; T cell receptor; Cytokine-induced killer cell; Program death-1; Cytotoxic lymphocyte antigen-4; Regulatory T cell; Dendritic cell; Myeloid-derived suppressor cell; PD-ligand 1; Peptide vaccine; Tumor-associated antigen; Tumor infiltrating lymphocyte
Core Tip Hepatocellular carcinoma (HCC) develops or recurs from non-cancerous liver lesions with chronic inflammatory states and/or cirrhosis, and these lesions cannot be cured and/or eradicated by local and/or drug therapies. Immune therapy may be effective for HCC treatment by preventing non-cancerous liver lesions from progressing to HCC as well as reducing tumor burdens. However, tumor immunity is frequently depressed in tumor sites, particularly in liver microenvironment, which is prone to exhibit immune tolerance, to reduce aberrant immune responses to massively-exposed antigens via portal veins. At present, cancer immune therapy employs two distinct strategies; enhancing the effector cell functions and unleashing the immune suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC.
Publish Date 2018-05-06 13:12
Citation Mukaida N, Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J Gastroenterol 2018; 24(17): 1839-1858
Url http://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm
DOI http://dx.doi.org/10.3748/wjg.v24.i17.1839
Full Article (PDF) WJG-24-1839.pdf
Manuscript File 38855-Review.docx
Answering Reviewers 38855-Answering reviewers.pdf
Audio Core Tip 38855-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 38855-Conflict-of-interest statement.pdf
Copyright License Agreement 38855-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 38855-Language certificate.pdf
Peer-review Report 38855-Peer-review(s).pdf
Scientific Misconduct Check 38855-Scientific misconduct check.pdf
Scientific Editor Work List 38855-Scientific editor work list.pdf